CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 336 enrolled
Drug / intervention
Isradipine +1 moredrug
Likely dose
Isradipine 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02168842
NCT02168842Phase 3Completed
CompareCT.gov

Phase 3 Double-blind Placebo-controlled Parallel Group Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease

University of Rochester·interventional·Posted Jun 20, 2014·Updated Jan 14, 2020

In Brief

A Phase 3 clinical trial evaluating Isradipine and Placebo (for Isradipine) for Parkinson Disease. Completed, enrolled 336 participants across 54 sites in 2 countries.

Detailed Summary

The purpose of the study is to determine whether treatment with isradipine is effective in slowing the progression of Parkinson disease disability.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson Disease
CountriesCanada, United States
CollaboratorsNational Institute of Neurological Disorders and Stroke (NINDS), Michael J. Fox Foundation for Parkinson's Research, The Parkinson Study Group

Timeline

Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJun 20, 2014
Enrollment StartNov 1, 2014
Primary CompletionNov 1, 2018
TodayJul 2, 2026
Enrollment to primary: 4 yearsPosted 12.0 years ago

Interventions

Isradipinedrug

Oral capsules Isradipine IR, up to 10 mg, taken twice daily

Placebo (for Isradipine)drug

Sugar Pill manufactured to look like Isradipine but has no active ingredients